Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received a consensus rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.33.

A number of brokerages recently weighed in on CNTX. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $4.00 price objective on the stock. D. Boral Capital started coverage on shares of Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $1.08 on Wednesday. The firm’s 50 day moving average price is $1.47 and its 200-day moving average price is $1.92. The company has a market cap of $81.00 million, a PE ratio of -1.19 and a beta of 2.10. Context Therapeutics has a 52-week low of $0.89 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Institutional investors have recently bought and sold shares of the stock. Great Point Partners LLC bought a new position in Context Therapeutics during the second quarter valued at $14,876,000. Blue Owl Capital Holdings LP bought a new position in Context Therapeutics during the second quarter valued at $10,348,000. Driehaus Capital Management LLC bought a new position in Context Therapeutics during the second quarter valued at $4,527,000. Nantahala Capital Management LLC bought a new position in Context Therapeutics during the second quarter valued at $3,881,000. Finally, Ally Bridge Group NY LLC lifted its position in Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after purchasing an additional 1,160,281 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.